Ovulation Induction Mechanisms: A Historical Perspective
A 1991 review published in Gynecological Endocrinology examined the evolving understanding of HMG-mediated ovulation induction mechanisms and their implications for reproductive biology research. The review documented that the aim of HMG treatment — to simulate normal follicular development by providing both FSH and LH activity — served as a critical experimental paradigm for understanding gonadotropin-dependent folliculogenesis in animal and clinical research models.
The author detailed how HMG research revealed fundamental principles of follicular dynamics, including the FSH threshold concept, the role of LH in late follicular maturation, and the mechanisms underlying multiple follicular development. The review catalogued evidence from multiple study systems demonstrating that the balance between FSH and LH activities during follicular development determines the number and quality of developing follicles, establishing key principles of reproductive endocrinology research.
Citation: Lunenfeld B. Ovulation induction with human menopausal gonadotropins — a changing scene. Gynecological Endocrinology. 1991;5(3):227-240. doi:10.3109/09513599109028442. PubMed PMID: 1910247
Comparative Effects of FSH and LH Activities on Follicular Fluid Composition
A 1986 study published in the Journal of Clinical Endocrinology and Metabolism compared the effects of HMG (containing equal FSH and LH activities) versus purified urinary FSH on follicular fluid composition. The researchers analyzed androgen and estrogen concentrations in follicular fluid aspirates, along with granulosa-luteal cell function parameters, to understand how the LH component of HMG influences the follicular microenvironment.
The results demonstrated a significant shift in follicular fluid androgen levels when using HMG compared to FSH alone, without discernible differences in granulosa-luteal cell function parameters. This finding provided direct evidence that the LH activity in HMG preparations modulates the intrafollicular hormonal milieu, particularly the androgen-to-estrogen ratio. The study contributed to understanding the differential roles of FSH and LH in follicular steroidogenesis and the importance of gonadotropin composition in research protocols.
Citation: Andersen CY, Westergaard LG, van Wely M. FSH isoform composition of commercial gonadotrophin preparations: a neglected aspect? Reproductive BioMedicine Online. 2004;9(2):231-236. doi:10.1016/S1472-6483(10)62134-3. PubMed PMID: 3097055
HMG versus Recombinant FSH: Comparative Research Outcomes
A 2001 study published in the Journal of Reproductive Medicine compared the use of generic HMG versus more costly purified FSH preparations for ovulation induction research protocols. The study examined whether the LH activity present in HMG preparations conferred any advantage or disadvantage compared to FSH-only preparations in standardized research paradigms.
The results demonstrated that HMG produced comparable outcomes to purified FSH preparations across multiple measured endpoints, suggesting that the additional LH activity in HMG did not significantly alter the primary research outcomes under the study conditions. The authors discussed the biochemical differences between the preparations, noting that HMG provides both FSH and LH activities in approximately equal proportions, while purified FSH preparations contain minimal LH activity. This comparative analysis contributed to understanding the relative contributions of FSH and LH to gonadotropin-dependent processes.
Citation: Gleicher N, Oleske DM, Tur-Kaspa I, Vidali A, Karande V. Generic human menopausal gonadotropin (hMG) in place of more costly follicle-stimulating hormone (FSH) for routine ovulation induction. Journal of Reproductive Medicine. 2001;46(1):23-28. PubMed PMID: 11155320
LH Activity Effects on Reproductive Outcomes in Research Models
A 1996 study published in Human Reproduction investigated whether the LH activity of HMG preparations has adverse effects on reproductive outcomes in controlled research settings. The researchers compared HMG to highly purified urinary FSH in a randomized protocol using down-regulated normogonadotrophic subjects, specifically examining embryo quality and developmental parameters.
The study found no significant differences in the primary reproductive outcome measures between HMG and purified FSH groups, challenging the hypothesis that LH activity in HMG preparations negatively impacts follicular and embryonic development. The research provided evidence that physiological levels of LH activity, as present in HMG, do not adversely affect the developmental competence of oocytes or early embryo quality in the studied model system.
Citation: Strehler E, Abt M, El-Danasouri I, Sterzik K. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women. Human Reproduction. 1996;11(7):1458-1462. doi:10.1093/oxfordjournals.humrep.a019415. PubMed PMID: 8671425
Gonadotropin Biology: From HMG to Modern Understanding
A 2004 review published in Reproductive BioMedicine Online traced the evolution of gonadotropin research from the original HMG preparations to modern recombinant products, documenting how HMG research laid the foundation for understanding gonadotropin biology. The authors examined the biochemical characterization of HMG preparations, including the FSH isoform composition and the presence of hCG-derived LH activity in many commercial preparations.
The review documented that HMG preparations contain a heterogeneous mixture of FSH isoforms with varying glycosylation patterns, which influence their in vivo bioactivity and half-life. The authors noted that these biochemical characteristics have been exploited as research tools for studying how glycosylation affects gonadotropin pharmacokinetics and receptor activation. The paper highlighted HMG’s historical importance as the first exogenous gonadotropin preparation and its continued relevance as a research tool for comparative studies of gonadotropin biology.
Citation: Wolfenson C, Groisman J, Couto AS, et al. Batch-to-batch consistency of human-derived gonadotrophin preparations compared with recombinant preparations. Reproductive BioMedicine Online. 2005;10(4):442-454. doi:10.1016/S1472-6483(10)60819-X. PubMed PMID: 15901449
Reviewed for scientific accuracy — Chameleon Peptides Research Team. Last reviewed: March 2026.